Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

Part of the following topical collections:
  1. Topical Collection on Systemic Lupus Erythematosus


Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.


Biologicals Targeted therapy Systemic lupus erythematosus SLE FDA Treatment Cutaneous lupus Belimumab Epratuzumab T cell inhibition 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Panopalis P, Clarke AE, Yelin E. The economic burden of systemic lupus erythematosus. Best Prac Res Clin Rheumatol. 2012;26:695–704.CrossRefGoogle Scholar
  2. 2.
    Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematous. Arthritis Rheum. 2006;54:2550–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Pineau CA. A comparison of damage accrual across different calendar periods in systemic lupus erythematosus patients. Lupus. 2006;15:590–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Balow JE, Austin HA 3rd. Renal disease in systemic lupus erythematosus. Rheum Dis Clin North Am. 1988;14:117–133.Google Scholar
  5. 5.
    • Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222. A flawed, but comprehensive study demonstrating that rituximab was less effective than believed for SLE.PubMedCrossRefGoogle Scholar
  6. 6.
    Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26.PubMedCrossRefGoogle Scholar
  7. 7.
    • Merrill JT, Borgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077–87. Did not meet its primary endpoint, but subanalysis indicated that this agent has efficacy for some SLE patients.PubMedCrossRefGoogle Scholar
  8. 8.
    Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized controlled phase III trial. Arthritis Rheum. 2008;58(8):2470–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Crosbie D, Black C, McIntyre L, et al. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev 2007; :CD005114.Google Scholar
  10. 10.
    Urowitz M, Isenberg D, Wallace DJ. Prelude—Edratide Phase-II study outcome—from predefined analyses to more recent assessment approaches. Ann Rheum Dis. 2011;70(S3):315. abstract.Google Scholar
  11. 11.
    Boumpas DR, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD 40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326(21):1373–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12.PubMedCrossRefGoogle Scholar
  14. 14.
    U.S. Food and Drug Administration. Guidance for Industry on Systemic Lupus Erythematosus: Developing Medical Products for Treatment. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM07263.pdf, Accessed March 11, 2013
  15. 15.
    Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288.PubMedGoogle Scholar
  16. 16.
    Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56:4113–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Wallace D, Strand V, Furie R, Petri M, Kalunian K, Pike M, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: Development of the BILAG based composite lupus assessment endpoint. Arthritis Rheum. 2011;63:S885–6.Google Scholar
  19. 19.
    Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Wofsy, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64:3660.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Hahn BH, Mc Machon MA, Wilkinson A, Wallace WD, Daikh D, Fitzgerald JD, et al. American College of Rheumatology Guidelines for Screening, Treatment and Management of Lupus Nephritis. Arthritis Care Res. 2012;64:797–808. The most comprehensive guidance document to date on managing lupus nephritis.CrossRefGoogle Scholar
  22. 22.
    Mosley K, Tam FW, Edwards RJ, et al. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford). 2006;45:1497.CrossRefGoogle Scholar
  23. 23.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.PubMedCrossRefGoogle Scholar
  24. 24.
    • Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30. A large study accompanying Ref. [25] which met its primary endpoints and enabled belimumab to receive FDA approval.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31. The largest, most detailed lupus clinical trial ever conducted.PubMedCrossRefGoogle Scholar
  26. 26.
    Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:3364–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:2328–37.PubMedCrossRefGoogle Scholar
  28. 28.
    van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Wallace D, Navarra S, Petri M, Gallacher A, Thomas M, Furie R, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus, Lupus. 2012 Dec 4. [Epub ahead of print]Google Scholar
  31. 31.
    Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14:R33. doi:10.1186/ar3738.PubMedCrossRefGoogle Scholar
  32. 32.
    Genovese MC, Bojin S, Biagini I, Mociran E, Cristei D, Mirea G, et al. Tabalumab in patients with rheumatoid arthritis with an inadequate response to methotrexate and naïve to biologic therapy. Arthritis Rheum. 2013. doi:10.1002/art.37820 [Epub ahead of print].PubMedGoogle Scholar
  33. 33.
    Stohl W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012;14(4):303–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Furie RA, Scheinberg MA, Leon G, et al. Blisbimod, an inhibitor of B cell activating factor, in patients with moderate-to-sever systemic lupus erythematosus. Arthritis Rheum. 2012;64:4169. abstract.Google Scholar
  35. 35.
    Wallace DJ, Goldenberg DM, Epratuzumab for SLE, Lupus 2013; in pressGoogle Scholar
  36. 36.
    Goldenberg DM et al. Trogocytosis as a mechanism of action of epratuzumab. Madrid: EULAR; 2013.Google Scholar
  37. 37.
    • Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled multicentre study, Ann Rheum Dis 2013 Jan 12, E Pub ahead of print. A large phase II trial demonstrating efficacy using the BICLA.Google Scholar
  38. 38.
    Wallace D, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo –controlled, multicenter studies (ALLEVIATE) and follow up. Rheumatology. 2013. doi:10.1093/rheumatology/ket129.PubMedGoogle Scholar
  39. 39.
    Jónsdóttir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330.PubMedCrossRefGoogle Scholar
  40. 40.
    Lehman TJA, Baird E, Ramanathan, et al. Prolonged improvement of systemic lupus erythematous following systemic administration of rituximab and cyclophosphamide. Arthritis Rheum. 2012;64. abstract 621.Google Scholar
  41. 41.
    Furie R, Nichols K, Cheng T-T, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind placebo controlled, Phase II/III study. Arthritis Rheum. 2011;63. abstract 2469.Google Scholar
  42. 42.
    Wallace DJ. Advances in drug therapy for systemic lupus erythematosus. BMC Med. 2010;8(77):1–19.Google Scholar
  43. 43.
    Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety profile and clinical activity of sifalumumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomized study. Annals Rhem Dis. 2011;70:1905–13.CrossRefGoogle Scholar
  44. 44.
    Mc Bride JM, Jiang J, Abbas A, Morimoto A, Li J, Maciuca R, et al. Safety and pharmacodynamics results of rontilzumab in a phase I, placebo-controlled, double-blind, dose-escalation study in systemic lupus erythematosus. Arthritis Rheum. 2012;64:3666–76.CrossRefGoogle Scholar
  45. 45.
    Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011;187(11):6143–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun. 2009;33(1):77–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Zimmer R, Wallace DJ, Muller S. Randomized, double-blind, placebo-controlled studies of P140 peptide in mannitol (Lupozor) and trehalose (Forigerimod) in patients with SLE. Arthritis Rheum. 2012;64:S1110.CrossRefGoogle Scholar
  48. 48.
    Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52.PubMedCrossRefGoogle Scholar
  49. 49.
    Nakou M, Papadimitraki ED, Fanouriakis A, Bertsias GK, Choulaki C, Goulidaki N, et al. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to generation of plasma B cells, Clin Exp Rheumatol. 2012 Nov 6. [Epub ahead of print]Google Scholar
  50. 50.
    Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S, Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial, Ann Rheum Dis. 2012 Nov 21.Google Scholar
  51. 51.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000–9.PubMedCrossRefGoogle Scholar
  52. 52.
    NCT01597058, Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions.Google Scholar
  53. 53.
    Furie R, Matis L, Rollins S, et al. A single dose, placebo-controlled, double blind, phase I study of the humanized anti-C5 antibody hbG1.1 in patients with systemic lupus erythematosus, Arthritis Rheum Abstract presented at the 64th Annual Scientific Meeting of the American College of Rheumatology, Philadelphia.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Cedars-Sinai Medical CenterDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.West HollywoodUSA

Personalised recommendations